Imagene’s OI Suite, powered by AI, utilizes CanvOI trained on 1.5M tissue samples to offer pharmaceutical companies an independent tool for hypothesis exploration. This versatile solution democratizes access to advanced AI tools, empowering translational research and clinical development teams to innovate and enrich their data. Whether cloud-based or on-premises, OI Suite eliminates the need for third-party developers, enabling teams to explore unlimited hypotheses with machine learning proficiency. Currently, these teams rely on single hypothesis projects, but OI Suite provides the flexibility to leverage AI and Real-World Data for comprehensive insights and advancements in precision oncology.
With the OI Suite, pharmaceutical companies can break free from traditional constraints and tap into the power of AI for enhanced precision oncology research. By democratizing access to advanced AI tools, Imagene’s solution opens up new possibilities for exploration and innovation in clinical trials. This shift towards independent hypothesis exploration marks a significant advancement in the field, offering a more efficient and effective approach to leveraging AI in pharmaceutical translational research. As the industry embraces AI-Powered Precision Oncology, Imagene’s OI Suite stands at the forefront, enabling teams to unlock the full potential of their data and drive meaningful progress in precision medicine.
Read more from pharmaceutical-technology.com
